{"id":7209,"date":"2024-01-12T12:02:33","date_gmt":"2024-01-12T17:02:33","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=7209"},"modified":"2024-01-12T12:02:35","modified_gmt":"2024-01-12T17:02:35","slug":"alcons-strategic-move-ar-15512-breakthrough-in-dry-eye-treatment","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/alcons-strategic-move-ar-15512-breakthrough-in-dry-eye-treatment\/","title":{"rendered":"Alcon&#8217;s Strategic Move: AR-15512 Breakthrough in Dry Eye Treatment"},"content":{"rendered":"\n<p>Alcon&#8217;s recent acquisition of Aerie Pharmaceuticals for $770 million is proving to be a strategic triumph, as their lead candidate, AR-15512, demonstrates promising results in two critical phase 3 trials for dry eye disease. Approximately 930 participants were randomized in these trials, with those receiving AR-15512 showcasing a noteworthy increase in tear production after a 14-day regimen, meeting the primary endpoint with a statistically significant p-value below 0.0001.<\/p>\n\n\n\n<p>Early observations by Alcon indicate tangible improvements in tear production from the very first day of treatment, and these effects endured throughout the 90-day observation period. While specific trial data remains undisclosed, Alcon is actively preparing to submit an application for FDA approval by mid-2024.&nbsp;<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script>\n<ins class=\"adsbygoogle\" style=\"display:block; text-align:center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p>Simultaneously, the company is concluding a comprehensive long-term safety study, underscoring its commitment to ensuring the drug&#8217;s effectiveness and safety.<\/p>\n\n\n\n<p>This development positions Alcon as a frontrunner in providing a groundbreaking treatment for dry eye disease, a prevalent condition affecting an estimated 38 million Americans. Of concern is that around 20 million of these cases remain undiagnosed, and less than 10% of those diagnosed currently opt for prescription drugs. Alcon&#8217;s novel approach with AR-15512, distinct from conventional treatments targeting inflammation, holds significant potential to address this unmet need.<\/p>\n\n\n\n<p>Unlike traditional therapies like Bausch + Lomb&#8217;s Xiidra, AR-15512 operates on a distinct mechanism linked to the TRPM8 receptor, associated with detecting ocular surface dryness.&nbsp;<\/p>\n\n\n\n<p>Recently disclosed results from Phase III clinical trials, COMET-2 and COMET-3, highlight AR-15512&#8217;s efficacy in improving the production of tears among dry eye patients. Alcon&#8217;s official release emphasized that the treatment led to a substantial proportion of patients achieving a significant improvement in tear production, reaching statistical significance by day 14.<\/p>\n\n\n\n<p>Alcon found the drug to be well-tolerated, with no serious side effects reported making it a viable option for patients with dry eye.<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script>\n<ins class=\"adsbygoogle\" style=\"display:block; text-align:center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p>Alcon CEO David Endicott expressed confidence in AR-15512&#8217;s potential to address the limitations of existing dry eye prescriptions. The drug&#8217;s swift onset of action meets a critical gap in current dry eye medications, presenting an encouraging prospect for individuals grappling with this chronic condition.<\/p>\n\n\n\n<p>Worth noting is the origin of AR-15512 from Aerie Pharmaceuticals, which Alcon acquired in August 2022.&nbsp;<\/p>\n\n\n\n<p>In contrast to recent setbacks in the dry eye disease domain, such as the FDA&#8217;s rejection of Aldeyra Therapeutics&#8217; reproxalap, Alcon&#8217;s AR-15512 instills renewed hope. The positive outcomes from COMET-2 and COMET-3 trials underscore the drug&#8217;s potential, charting a promising trajectory for an FDA application in mid-2024.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alcon&#8217;s recent acquisition of Aerie Pharmaceuticals for $770 million is proving to be a strategic triumph, as their lead candidate, AR-15512, demonstrates promising results in two critical phase 3 trials for dry eye disease. Approximately 930 participants were randomized in these trials, with those receiving AR-15512 showcasing a noteworthy increase in tear production after a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7210,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-7209","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/7209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=7209"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/7209\/revisions"}],"predecessor-version":[{"id":7211,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/7209\/revisions\/7211"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/7210"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=7209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=7209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=7209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}